| Target/MOA |
Code |
Indiacation |
Stage |
| Drug Discovery |
Pro-Clinical |
IND enabling |
Phase I |
Phase II |
Phase III |
| CTLA-4 |
ONC-392 |
Tumor |
|
| CTLA-4 |
A1-061 * |
Tumor |
|
| CD24/SIGLEC |
A1-071 * |
Inflammatory Disease |
|
| CD24/SIGLEC |
ONC-841 |
Tumor |
|
| CD24/SIGLEC |
ONC-783 |
Tumor |
|
| CD24/SIGLEC |
ONC-784 |
Tumor |
|
* Clinical studies have been conducted in Australia.
